News Releases

November, 2018

November 23, 2018 2018-11-23 Takeda Canada and Game Yuceland Featured in CPM

October, 2018

October 23, 2018 2018-10-23 ENTYVIO® study data achieves and maintains clinical remission and mucosal healing in moderately to severely active ulcerative colitis

September, 2018

September 10, 2018 2018-09-10 PATIENT SUPPORT PROGRAM FOR METASTATIC LUNG CANCER PATIENTS

July, 2018

July 30, 2018 2018-07-30 New Treatment Option for Canadians with Metastatic Lung Cancer

June, 2018

June 12, 2018 2018-06-12 Gamze Yüceland appointed General Manager of Takeda Canada

June 5, 2018 2018-06-05 Takeda Canada supports Quebec early clinical research initiative with contribution to CATALIS

June 5, 2018 2018-06-05 Analysis of real-world safety data shows gut-selective ENTYVIO® (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFα-antagonist therapy in ulcerative colitis and Crohn's disease patients

February, 2018

February 20, 2018 2018-02-20 ENTYVIO vedolizumab Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy